FinanceAsianet Newsable
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years
in5points
ZVRA stock fell pre-market after EMA recommended refusal of marketing authorization for Zevra's Meplyffa.
Meplyffa is a medicine intended for treating Niemann-Pick disease type C.
The stock is heading for its worst day in over 5 years.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically